PTC/SB/08x (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

U.S. Patent and Trademask Office; U.S. DEPARTMENT OF CC Under the Paperwork Reduction Act of 1995, no persons are required to respond to acallection of information unless it contains a valid OMS conti-

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number			
	Filing Date		2006-08-31	
	First Named Inventor Andre		reas Noack	
	Art Unit			
	Examiner Name			
	Attorney Docket Number	er	9771-013US	

					U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code1 Issue Date Name of Patentee or Applicant of cited Document		Releva		Lines where ges or Relev				
	1	4117116		1978-0	9-26	Buehler et al.					
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	l lease click the	Add button.	_	Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	of sited Desument		Releva	Columns, int Passag s Appear	Lines where ges or Relev	e vant
	1										
If you wis	h to a	dd additional U.S. Publ	ished Ap	p		, , , , , , , , , , , , , , , , , , , ,		d button	$\overline{}$		
				FOREIG	SN PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ²		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	e or	vhere Rel	or Relevant	74
	1	3203479A1	DE			1983-08-11	Röhm Pharma Gr	bH			
	2	2759032	DE			1979-07-12	Egyt Gyogyszervegyes Gyar	zeti			
	3	3727417A1	DE			1989-03-02	Pharm Elan GmbH				

	Application Number		
NEODWATION DIGGS COURT	Filing Date		2006-08-31
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Andre	eas Noack
Not for submission under 37 CFR 1.99)	Art Unit		
,	Examiner Name		
	Attorney Docket Numb	or	9771.013115

If you wisl	h to a	additional Foreign Patent Document citation information please click the Add button Add	
		NON-PATENT LITERATURE DOCUMENTS Remove	
Examiner Initials*	Cite No	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Тs
	1		
If you wis	h to a	additional non-patent literature document citation information please click the Add button Add	_
		EXAMINER SIGNATURE	
Examiner	Signa	ure Date Considered	
*EVAMIN	ED: I-	iel If reference considered upather or not citation in in conformance with MDED CO. Draw line through a	_

Take Kint Code of USPTO Platent Documents at year, USPTO_GOLY or MEPP 901.6. * Enter office that issued the document, by the how-letter code (WIPO Standard ST.3.) **For Liganeses petant documents, the decision to the year of the reign or the Engerer runt precision be sent in unbread for high petant document. **Incl of Cournert by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. **Applicant is to place a check mark here (English Insquages transitions in addition.**)

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Application Number Fling Date 2006-08-31 First Number (Not for submission under 37 CFR 1-99) First Number Number (Not for submission under 37 CFR 1-99) First Number Numbe

CERTIFICATION STATEMENT

Please see 37	CFR 1.97 and	1.98 to make the appropriate selection(s):
---------------	--------------	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eVI).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.5(r)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Jason Paul DeMont/	Date (YYYY-MM-DD)	2006-08-29
Name/Print	Igeon Davil DeMont	Registration Number	35793

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenian's (Office, U.S. Operatment of Commence, P. 0. Bast 1450, Alexandria, V.32.11-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.32.211-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.